JP2003504303A5 - - Google Patents

Download PDF

Info

Publication number
JP2003504303A5
JP2003504303A5 JP2000584874A JP2000584874A JP2003504303A5 JP 2003504303 A5 JP2003504303 A5 JP 2003504303A5 JP 2000584874 A JP2000584874 A JP 2000584874A JP 2000584874 A JP2000584874 A JP 2000584874A JP 2003504303 A5 JP2003504303 A5 JP 2003504303A5
Authority
JP
Japan
Prior art keywords
disorder
disorders
symptoms
cognitive
sibutramine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000584874A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003504303A (ja
Filing date
Publication date
Priority claimed from US09/204,124 external-priority patent/US6323242B1/en
Application filed filed Critical
Publication of JP2003504303A publication Critical patent/JP2003504303A/ja
Publication of JP2003504303A5 publication Critical patent/JP2003504303A5/ja
Pending legal-status Critical Current

Links

JP2000584874A 1998-12-02 1999-12-01 器質性障害から派生する障害の治療 Pending JP2003504303A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/204,124 US6323242B1 (en) 1998-12-02 1998-12-02 Treatment of disorders secondary to organic impairments
US09/204,124 1998-12-02
PCT/US1999/028362 WO2000032178A2 (en) 1998-12-02 1999-12-01 Use of siburamine for the treatment of disorders of the central nervous system secondary to organic impairments

Publications (2)

Publication Number Publication Date
JP2003504303A JP2003504303A (ja) 2003-02-04
JP2003504303A5 true JP2003504303A5 (https=) 2007-02-01

Family

ID=22756736

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000584874A Pending JP2003504303A (ja) 1998-12-02 1999-12-01 器質性障害から派生する障害の治療

Country Status (8)

Country Link
US (2) US6323242B1 (https=)
EP (1) EP1135115B1 (https=)
JP (1) JP2003504303A (https=)
AT (1) ATE329588T1 (https=)
AU (1) AU764049B2 (https=)
CA (1) CA2353133C (https=)
DE (1) DE69931957T2 (https=)
WO (1) WO2000032178A2 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339106B1 (en) * 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6696495B2 (en) * 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
US6803387B1 (en) * 1999-03-19 2004-10-12 Abbott Gmbh & Co. Kg Treatment of neuropathic pain or fibromyalgia
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
CA2438816A1 (en) * 2001-02-22 2002-09-06 Classen Immunotherapies, Inc. Improved algorithms and methods for products safety
US7842307B2 (en) * 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US6635675B2 (en) * 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
CA2466649A1 (en) * 2001-11-30 2003-06-12 Eli Lilly & Company Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
WO2003086372A2 (en) * 2002-04-10 2003-10-23 University Of Florida Methods of treating medication-, substance-, disease-, and other medical condition-related sexual dysfunction
CN1662231A (zh) * 2002-04-24 2005-08-31 柏树生物科学公司 包括应激相关障碍在内的功能性躯体障碍的预防与治疗
CA2484482C (en) 2002-05-30 2011-07-26 Neurosearch A/S Triple monoamine reuptake inhibitors for the treatment of chronic pain
US20070032554A1 (en) * 2003-08-27 2007-02-08 Elililly And Company A Corporation Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors
WO2006083204A1 (en) * 2004-12-27 2006-08-10 Alpha 2 Pharmaceutical Ab Antidepressant medicament comprising idazoxan and a selective serotonin reuptake inhibitor
EP1938811A4 (en) * 2005-09-22 2008-12-17 Eisai R&D Man Co Ltd MEDICAL COMPOSITION FOR THE TREATMENT OF BULAMINE AND BULAMIC DEPRESSIONS
GEP20125432B (en) 2005-10-12 2012-03-26 Unimed Pharmaceuticals Llc Improved testosterone gel and use thereof
CA2663254C (en) 2006-09-15 2016-04-19 Reviva Pharmaceuticals, Inc. Synthesis, methods of using, and compositions of cycloalkylmethylamines
WO2008042773A2 (en) * 2006-09-29 2008-04-10 Pdxrx, Inc. Unitary pharmaceutical composition, method, and kit for the treatment or prevention of metabolic or endocrine disorders
WO2008051610A2 (en) * 2006-10-26 2008-05-02 Mclean Hospital Corporation, The Treatment of impulse control disorders
WO2012003501A2 (en) 2010-07-02 2012-01-05 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
US9238625B2 (en) 2011-12-30 2016-01-19 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives
US11033554B2 (en) * 2015-07-24 2021-06-15 United States Government As Represented By The Department Of Veterans Affairs Use of dopamine and serotonin receptor antagonists for treatment in a subject with retinal degeneration
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
KR20200085730A (ko) * 2017-09-07 2020-07-15 엔엘에스-1 파마 아게 헤로인 의존성 및 물질 사용 장애에 대한 마진돌 치료

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443449A (en) 1981-04-06 1984-04-17 The Boots Company Limited Arylcyclobutylalkylamines and anti-depression composition and methods using same
ZA821577B (en) 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
GB8531071D0 (en) 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB8704777D0 (en) 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5780051A (en) 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
CA2139000A1 (en) * 1992-06-23 1994-01-06 James W. Young Methods and compositions for treating depression and other disorders using optically pure(+) sibutramine
CA2138998A1 (en) 1992-06-23 1994-01-06 James W. Young Methods and compositions for treating depression and other disorders using optically pure(-) sibutramine
US5459164A (en) 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
GB9402641D0 (en) 1994-02-11 1994-04-06 Boots Co Plc Therapeutic agents
US5663178A (en) 1995-02-06 1997-09-02 Eli Lilly And Company Tetrahydro-beta carbolines
GB9406857D0 (en) 1994-04-07 1994-06-01 Sandoz Ltd Improvements in or relating to organic compounds
GB9619757D0 (en) 1996-09-21 1996-11-06 Knoll Ag Chemical process
GB9619961D0 (en) 1996-09-25 1996-11-13 Knoll Ag Medical treatment
US5908830A (en) 1996-10-31 1999-06-01 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
US5795880A (en) 1996-12-30 1998-08-18 Louisiana State University Medical Center Foundation Method and composition for treating obesity and related disorders in animals comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent
US5804596A (en) 1997-02-27 1998-09-08 Sabinsa Corporation Method of preparing a forskohlin composition from forskohlin extract and use of forskohlin for promoting lean body mass and treating mood disorders
US5922341A (en) 1997-10-28 1999-07-13 Vivus, Incorporated Local administration of pharmacologically active agents to treat premature ejaculation
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6075028A (en) 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders

Similar Documents

Publication Publication Date Title
JP2003504303A5 (https=)
Anglin et al. History of the methamphetamine problem
AU782656B2 (en) Treatment of fatigue, head injury and stroke
JP2022515766A5 (https=)
KR20250114110A (ko) 약물 활성의 조절제로서의 부프로피온
AU764049B2 (en) Treatment of disorders secondary to organic impairments
JP2009506069A5 (https=)
WO2004110387A3 (en) Sigma ligands for neuronal regeneration and functional recovery
JP2007530622A5 (https=)
JP2021512920A5 (https=)
JP2002525280A5 (https=)
WO2006019886A3 (en) Pyrrolo(oxo)isoquinolines as 5ht ligands
CN103041389A (zh) 使用毒蕈碱型受体m1拮抗剂治疗心理学病况
FI3825306T3 (fi) Morfinaaniyhdisteitä
JP2004533445A5 (https=)
JP2007505156A5 (https=)
JP2009502914A5 (https=)
JP2011516604A (ja) 鬱病患者の自殺行動の予防治療のためのミルナシプラン塩酸塩の（１ｓ，２ｒ）鏡像異性体の使用
JP2006517567A5 (https=)
Kjellgren et al. The quest for well-being and pleasure: experiences of the novel synthetic opioids AH-7921 and MT-45, as reported by anonymous users online.
JP2008507550A5 (https=)
CN101472571B (zh) 毒蕈碱型受体m1拮抗剂在制备治疗心理学病况药物中的应用
IL194346A0 (en) Peptide substance stimulating regeneration of central nervous system neurons, pharmaceutical composition on its base, and the method of its application
JP2009532369A5 (https=)
JP2003524573A5 (https=)